series-a
Stage
About
Excellergy Inc develops a novel class of allergy therapeutics called Effector Cell Response Inhibitors (ECRIs) that disable the IgE axis to rapidly and effectively control severe allergic diseases by removing IgE from allergic effector cells and preventing re-sensitization.
Explore Excellergy Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.